The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer

This study tests whether adding the immunotherapy drug tislelizumab to standard pre-operative chemotherapy improves outcomes in patients with a specific type of rectal cancer called MSS (microsatellite stable) — a type that typically does not respond well to immunotherapy on its own. The treatment is given before surgery to try to shrink the tumor. **You may be eligible if...** - You are aged 18–70 with confirmed MSS rectal cancer that has not spread to distant organs - Your tumor is located within 12 cm of the anal opening - Imaging shows your tumor has grown into surrounding tissues or spread to nearby lymph nodes (T3-4 or N+) - You have not received any prior treatment for this cancer - Your general health status is good (ECOG 0–1) **You may NOT be eligible if...** - Your cancer has spread to distant organs (metastatic) - You have received prior anti-cancer therapy - You have active autoimmune disease or other conditions that make immunotherapy unsafe - Your organ function is inadequate Talk to your doctor to see if this trial is right for you.